Researchers have developed a unique delivery mechanism that inhibits the respiratory syncytial virus using double-stapled peptides and nanoparticles. They believe their research has implications for the treatment of other viruses as well.
Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale. Last year's report highlighted some companies that have since made an even bigger impact in biotech as a whole, including the newly public Bind Therapeutics and hot RNAi specialist Alnylam. You'll see familiar names in both the industry and the academic realm in this year's report, among others that have offered important developments to the arena. Check out the report >>
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
Researchers at Harvard University's Wyss Institute have developed "smart" nanoparticles out of DNA that act like a virus to bypass the immune system's defenses and deliver drugs to a tumor.
Mylan Pharmaceutical's Xulane is the first generic contraceptive transdermal patch to hit the market, marking another milestone for the delivery technology.
Researchers at the University of Texas at Arlington found that nanoparticles they were studying for radiation detection in the security arena could produce a toxic byproduct able to damage cancer cells.
One way of bypassing the immune system to deliver drugs to a tumor site is to use the immune system itself as a delivery mechanism. And now researchers have unexpectedly found that nanoparticle-encased drugs injected into mice entered immune cells called monocytes, which then carry the treatment to the correct site.
Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech.
A team of scientists from Oregon State University and Aradigm, a small pulmonary device company out of California, touted successful in vitro results for its inhaled, encapsulated ciproflaxacin treatment for infections associated with the lungs.
From Our Sister Sites
A hybrid international biotech upstart with deep U.S. academic roots, a company base in Basel and a plan to grow its research operations in London has landed a $25 million A round to launch another effort at gene editing using CRISPR/Cas9 technology--one of the hottest emerging fields in drug development.
Lombard Medical revived plans to go public with a revised stateside IPO. The news comes less than two weeks after the company decided to postpone its public offering, citing poor market conditions.